# Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma

> **NCT01615029** · PHASE1,PHASE2 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 45 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Part 1 (Dose Escalation): Daratumumab
- **DRUG:** Part 2 (Dose Expansion): Daratumumab
- **DRUG:** Lenalidomide
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT01615029
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06-26
- **Primary completion:** 2015-10-02
- **Final completion:** 2024-10-23
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2026-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01615029

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01615029, "Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01615029. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*